Navigation Links
Smith & Nephew Endoscopy Launches New, Reusable Cannula Line for Hip Arthroscopy

ANDOVER, Mass., May 19 /PRNewswire-FirstCall/ -- Smith & Nephew's (NYSE: SNN; LSE: SN) Endoscopy Division today announced the launch of the ARTHROGARDE(TM) Hip Access Cannula, designed to prevent inadvertent damage to soft tissue that can occur during arthroscopic hip repair surgery.

During arthroscopy, surgeons frequently use a cannula to create a sterile pathway to the joint. They insert specialized devices through the cannula to diagnose and, if needed, repair damaged tissue in the joint. One challenge for surgeons has long been accessing the difficult-to-reach hip joint cavity without damaging the delicate cartilage surfaces within the joint.

The rounded ends of the ARTHROGARDE Hip Access Cannula provide a smooth surface to protect soft tissue as it penetrates the hip and enters the joint socket. The cannula wall has been thickened to provide additional strength and prevent bending or wear and tear over time.

"Surgeons are keenly aware of the potential for instrument-induced damage due to the nature of the hip anatomy," said Lisa Donnelly, Smith & Nephew Endoscopy's market manager for hip repair. "We have learned a great deal since producing the first generation of cannulas for hip arthroscopy, and with ARTHROGARDE, we've put that experience to good use for the benefit of our surgeons and their patients."

The line includes reusable closed cannulas in three sizes (4.5mm, 5.0mm, 5.5mm), as well as a slotted cannula which allows the surgeon to utilize larger, and/or curved instruments which do not fit down a standard closed cannula. The slotted cannula features a spoon-like design at the tip to provide cartilage protection. The Slotted Hip Access Cannula has a redesigned grip that makes the cannula more stable and resistant to bending.

"The new ARTHROGARDE Hip Access Cannula series was designed to reduce the possibility of inadvertent injury to cartilage when performing hip arthroscopy. Testing demonstrated that it was difficult to damage the cartilage even when it was intended," said Dr. Victor Ilizaliturri, a professor of hip and knee surgery at the National Autonomous University of Mexico and Chief of Adult Joint Reconstruction at the National Rehabilitation Institute of Mexico in Mexico City. "These new devices will be viewed as a welcome addition to hip arthroscopy instrumentation for surgeons who are both new to hip arthroscopy and experienced practitioners."

Contact: Joe Metzger

Vice President, Corporate Communications

Smith & Nephew Endoscopy

(978) 749-1330

About Us

Smith & Nephew is a global medical technology business, specializing in Orthopaedic Reconstruction, Orthopaedic Trauma and Clinical Therapies, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the leading global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The Company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The Company operates in 32 countries around the world. Annual sales in 2007 were nearly $2.8 billion.

Forward-Looking Statements

This press release contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In particular, statements regarding planned growth in our business and in our operating margins discussed under "Outlook" are forward-looking statements as are discussions of our product pipeline. These statements, as well as the phrases "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions, are generally intended to identify forward-looking statements. Such forward- looking statements involve known and unknown risks, uncertainties and other important factors (including, but not limited to, the outcome of litigation and regulatory approvals) that could cause the actual results, performance or achievements of Smith & Nephew, or industry results, to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20F, for a discussion of certain of these factors.

All forward-looking statements in this press release are based on information available to Smith & Nephew as of the date hereof. All written or oral forward-looking statements attributable to Smith & Nephew or any person acting on behalf of Smith & Nephew are expressly qualified in their entirety by the foregoing. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement contained herein to reflect any change in Smith & Nephew's expectation with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

SOURCE Smith & Nephew, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
2. GlaxoSmithKline Commences Tender Offer to Acquire Sirtris Pharmaceuticals
3. GlaxoSmithKline to Acquire Sirtris Pharmaceuticals, a World Leader in Sirtuin Research and Development
4. Smiths Medical to Promote and Distribute Abbotts FreeStyle Navigator Continuous Glucose Monitoring System
5. Holly Smith Joins Profect as Director of Clinical Imaging Services
6. Pharmacopeia to Receive $5 Million Payment from GlaxoSmithKline
7. Ingenuity Systems Extends Enterprise-Level Software Agreement With GlaxoSmithKline
8. Vaccinex Antibody Licensed to GlaxoSmithKline
9. Smithfield Foods, Inc. Statement Regarding Animal Cloning
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine Exhibitions and Universal Partnerships ... opening in March 2016 at Melbourne Museum in Melbourne, Australia. Immediately following the ... American tour dates. The Exhibition is based on Universal Pictures’ Jurassic World, one ...
(Date:11/30/2015)... -- Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, ... Inc., a leading genome informatics company offering highly accurate, ... San Diego -based company has 14 ... Ashley Van Zeeland , Ph.D., who is now ... the deal were not disclosed. Van ...
(Date:11/30/2015)... -- HUYA Bioscience International, the leader in accelerating global development ... announced it has signed a Memorandum of Understanding with ... between KDDF and HUYA with the ultimate goal of ... the global market. China,s ... preclinical and clinical stage compounds. The company advances the ...
(Date:11/30/2015)... , Nov. 30, 2015  AbbVie, is introducing ... focuses on a daily routine for managing the life-long ... medication can affect the way the body absorbs it ... their a daily routine are important. The goal of ... patients better manage their hypothyroidism by establishing a daily ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Based on its in-depth analysis of the ... with the 2015 Global Frost & Sullivan Award for ... presents this award to the company that has developed ... of the market it serves. The award recognizes the ... on customer base demands, the overall impact it has ...
(Date:11/18/2015)... 18, 2015 --> ... new market report titled  Gesture Recognition Market - Global ... - 2021. According to the report, the global gesture recognition market was ... to reach US$29.1 bn by 2021, at a CAGR ... North America dominated the global gesture recognition ...
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
Breaking Biology News(10 mins):